The case for & against
Bull & Bear analysis
Bearish
InMed Pharmaceuticals, Inc. (NASDAQ: INM) is a biotechnology company focused on developing cannabinoid-based therapies, specifically targeting rare diseases such as epidermolysis bullosa and glaucoma. The company is gaining traction in the cannabinoid sector through its proprietary Integrison platform that allows for the scalable production of rare cannabinoids, bolstering its position in the health and wellness markets. InMed is navigating a challenging economic environment, yet remains optimistic about its strategic initiatives and potential for growth amidst the evolving therapeutic landscape.
Bull says
- ↑INM-755 Phase II trial and INM-088 glaucoma program bolster pipeline prospects
- ↑BayMedica deal adds production for rare cannabinoids, $1.1 M early revenues
- ↑Recent $11 M capital raise extends R&D runway into late 2023
- ↑Cannabinoid therapeutics market growing rapidly in rare-disease segment
- ↑Positive growth, liquidity, and analyst revision factors support upside
Bear says
- ↓FY22 net loss doubled to $18.6 M as R&D and G&A rose to $7.3 M
- ↓Cash and equivalents of $6.2 M fund operations only into H2 2023 without further financing
- ↓Market for rare cannabinoids showing slower-than-expected uptake
- ↓Regulatory approval delays could stall INM-755 and INM-088 trials
- ↓Intense competition from larger pharma threatens market share
- ↓Negative earnings yield, weak profitability, and negative momentum factors persist
Earnings Call · Q3 2021 · Mgmt. Guidance
Updated 08-30-2026bullish
Transcript signals
Bull points
- We believe these important milestones bring us a step closer to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs.
- The start of the 201 trial will mark an important milestone as the first time a cannabinol product will be entering a Phase II efficacy clinical trial for potential therapeutic use.
- a level of 2 grams per liter cannabinoid yield, a milestone that signals commercial viability and supports advancement to large-scale production in the coming months.
Bear points
- We will import these compounds and initiate our preclinical testing ASAP. We believe the synergy of this collaboration will give us important knowledge in furthering the development of our Integrison approach and the compounds it may be able to cost-effectively produce.
- Over the three months ended March 31st, 2021, the company recorded a net loss of approximately 3.1 million or 41 cents per share compared with a net loss of 2 million or 39 cents per share for the three months ended March 31st, 2020.
- Over the three months ended March 31st, 2021, the company recorded a net loss of approximately 3.1 million or 41 cents per share compared with a net loss of 2 million or 39 cents per share for the three months ended March 31st, 2020.
Read full transcript analysis ›